Shenzhen-based Eureka Biotechnology, a company specializing in comprehensive solutions for the cell and gene therapy industry, has reportedly secured RMB 100 million (USD 14.97 million) in a Series B financing round. The funding, led by Eight Roads Capital and joined by Shenzhen Jiufite Private Equity Investment Management and Juke Investment, will support the company’s R&D in cell therapy intelligent production equipment and viral vector large-scale production technology, as well as domestic and international market expansion.
Company Background and Technology
Founded in 2014, EurekaBio Technology has established itself as a key player in the cell and gene therapy sector. The company is known for its fully enclosed automated cell processing system, CellSep PRO, which facilitates standardized production of various cell therapy products. Additionally, EurekaBio boasts a stable cell line-based lentiviral vector production system, underscoring its commitment to advancing therapeutic solutions through innovative technology.
Future Outlook
With the fresh capital, EurekaBio aims to further enhance its technological capabilities and market presence. By investing in R&D and expanding its production technologies, the company is positioned to play a significant role in the evolving landscape of cell and gene therapies globally.-Fineline Info & Tech
